Longeveron Inc. (NASDAQ:LGVN – Get Free Report) was the target of a significant growth in short interest in October. As of October 30th, there was short interest totaling 157,139 shares, a growth of 114.7% from the October 15th total of 73,177 shares. Currently, 5.3% of the shares of the stock are short sold. Based on an average daily volume of 72,097 shares, the short-interest ratio is currently 2.2 days.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on LGVN. Wall Street Zen lowered shares of Longeveron from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings lowered Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Longeveron presently has an average rating of “Hold” and an average target price of $80.00.
Hedge Funds Weigh In On Longeveron
A hedge fund recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC acquired a new stake in Longeveron Inc. (NASDAQ:LGVN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned about 0.86% of Longeveron as of its most recent filing with the Securities and Exchange Commission (SEC). 10.01% of the stock is owned by institutional investors.
Longeveron Stock Down 7.1%
Shares of Longeveron stock traded down $0.18 on Monday, hitting $2.31. 21,659 shares of the company were exchanged, compared to its average volume of 205,689. The stock has a market capitalization of $7.38 million, a price-to-earnings ratio of -0.29 and a beta of -0.09. The company has a 50-day moving average price of $2.92 and a 200 day moving average price of $6.44. Longeveron has a 1-year low of $1.31 and a 1-year high of $12.30.
Longeveron (NASDAQ:LGVN – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($1.91) EPS for the quarter, missing the consensus estimate of ($1.70) by ($0.21). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.80 million. Longeveron had a negative net margin of 1,921.72% and a negative return on equity of 243.26%. Research analysts forecast that Longeveron will post -7.20 EPS for the current year.
Longeveron Company Profile
Longeveron Inc. is a clinical-stage biotechnology company based in Miami, Florida, developing cell-based therapies for serious and age-related conditions. Its research focuses on medicinal signaling cells, a type of adult stem cell that may influence the body’s repair and immune responses. The company’s lead product candidate, Lomecel-B, is an investigational therapy made from donated bone marrow cells. Longeveron has studied it for conditions including hypoplastic left heart syndrome, Alzheimer’s disease and aging-related frailty.
Read More
- Five stocks we like better than Longeveron
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
